3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Endocrine
1
CNS
1
Conditions
von Hippel-Lindau Disease
1
Pheochromocytoma
1
Paraganglioma
1
Adenoma, Islet Cell
1
Interventions
TIC10 compound
5
trametinib
4
dabrafenib
4
Crizotinib
3
selpercatinib
2
naxitamab
2
entrectinib
2
Trastuzumab
2
Granulocyte-Macrophage Colony-Stimulating Factor
2
AZD 6244
2
vorasidenib
1
ulixertinib
1
tucatinib
1
trastuzumab biosimilar HLX02
1
tovorafenib
1
sodium thiosulfate
1
sapanisertib
1
sacituzumab govitecan
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
mirdametinib
1
lutetium Lu 177 dotatate
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
defactinib
1
copper dotatate CU-64
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
belzutifan
×
CNS
×
Clear all
NCT04924075
2026-05-28
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
322 enrolled
1 FDA